Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

from TRITON-TIMI 38 (see section 4.2.15). 4.3 Consideration of the evidence The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of prasugrel, having considered evidence on the nature of acute coronary syndromes and the value placed on the benefits of prasugrel by people with the condition, those who represent them, and clinical specialists. It also took into account the effective use of NHS resources. Clinical effectiveness 4.3.1 The Committee discussed the clinical management of acute coronary syndromes. The Committee heard from the clinical specialists that current management is in line with NICE's technology appraisal guidance 182 on prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention as well as NICE's technology appraisal guidance on ticagrelor for the treatment of acute coronary syndromes, Myocardial infarction with ST-segment-elevation: The acute management of myocardial infarction with ST-segment-elevation (now replaced by NICE's guideline on acute coronary syndromes) and Unstable angina and NSTEMI: early management (now replaced by NICE's guideline on acute coronary syndromes). The Committee understood that, in England, treatment options for people with STEMI are prasugrel in combination with aspirin, ticagrelor in combination with low-dose aspirin or clopidogrel in combination with low-dose aspirin, along with percutaneous
